Wittouck Amaury
CIK 0001841311 Name as filed on the most recent filing
Filed as Wittouck Amaury (22)
29 transaction lines · from 22 filings · filed 2021-02-03 to 2026-06-17 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Cava Group, Inc. 6 filings
- ISSUER Scholar Rock Holding Corp 6 filings
- ISSUER Lexicon Pharmaceuticals, Inc. 3 filings
- ISSUER WW International, Inc. 1 filings
- ISSUER Glycomimetics Inc 4 filings
- ISSUER Omega Therapeutics, Inc. 1 filings
- ISSUER Seer, Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-15 |
Cava Group, Inc. CAVA |
S, Open-market sale | 3,000,000 disposed | 90.30 | 270,900,000.00 | Form 4, filing 0001193125-26-274180 | |
| 2024-11-18 |
Cava Group, Inc. CAVA |
S, Open-market sale | 8,000,000 disposed | 134.13 | 1,073,040,000.00 | Form 4, filing 0000950170-24-129313 | |
| 2024-08-26 |
Cava Group, Inc. CAVA |
S, Open-market sale | 6,000,000 disposed | 116.36 | 698,160,000.00 | Form 4, filing 0000950170-24-101420 | |
| 2024-06-05 |
Cava Group, Inc. CAVA |
S, Open-market sale | 3,000,000 disposed | 87.25 | 261,750,000.00 | Form 4, filing 0000950170-24-070715 | |
| 2024-03-21 |
Cava Group, Inc. CAVA |
S, Open-market sale | 2,000,000 disposed | 66.25 | 132,500,000.00 | Form 4, filing 0001193805-24-000441 | |
| 2024-02-27 |
Cava Group, Inc. CAVA |
S, Open-market sale | 3,500,000 disposed | 53.60 | 187,600,000.00 | Form 4, filing 0001193805-24-000286 | |
| 2023-10-12 |
Scholar Rock Holding Corp SRRK |
P, Open-market purchase | 2,189,781 acquired | 6.85 | 14,999,999.85 | Form 4, filing 0000950170-23-053600 | |
| 2023-10-12 |
Scholar Rock Holding Corp SRRK |
P, Open-market purchase | 10,150 acquired | 8.55 | 86,735.81 | Form 4, filing 0000950170-23-053600 | |
| 2023-06-05 |
Lexicon Pharmaceuticals, Inc. LXRX |
P, Open-market purchase | 27,775,050 acquired | 2.60 | 72,215,130.00 | Form 4, filing 0000899243-23-014464 | |
| 2023-05-10 |
WW International, Inc. WW |
S, Open-market sale | 14,818,300 disposed | 7.15 | 105,950,845.00 | Form 4, filing 0000899243-23-012682 | |
| 2023-04-28 |
Scholar Rock Holding Corp SRRK |
P, Open-market purchase | 31,557 acquired | 6.43 | 202,845.24 | Form 4, filing 0000899243-23-012043 | |
| 2023-02-24 |
Glycomimetics Inc GLYC |
P, Open-market purchase | 100,000 acquired | 1.70 | 170,000.00 | Form 4, filing 0000899243-23-006426 | |
| 2023-02-23 |
Glycomimetics Inc GLYC |
P, Open-market purchase | 200,000 acquired | 1.75 | 350,760.00 | Form 4, filing 0000899243-23-006027 | |
| 2023-02-22 |
Glycomimetics Inc GLYC |
P, Open-market purchase | 150,000 acquired | 1.79 | 268,995.00 | Form 4, filing 0000899243-23-006027 | |
| 2023-02-21 |
Glycomimetics Inc GLYC |
P, Open-market purchase | 50,000 acquired | 1.85 | 92,500.00 | Form 4, filing 0000899243-23-006027 | |
| 2023-02-17 |
Glycomimetics Inc GLYC |
P, Open-market purchase | 200,000 acquired | 1.70 | 341,000.00 | Form 4, filing 0000899243-23-005502 | |
| 2023-02-16 |
Glycomimetics Inc GLYC |
P, Open-market purchase | 315,266 acquired | 1.68 | 531,128.63 | Form 4, filing 0000899243-23-005502 | |
| 2023-02-15 |
Glycomimetics Inc GLYC |
P, Open-market purchase | 1,000,000 acquired | 2.16 | 2,155,800.00 | Form 4, filing 0000899243-23-005502 | |
| 2023-02-09 |
Glycomimetics Inc GLYC |
P, Open-market purchase | 11,451 acquired | 3.24 | 37,123.00 | Form 4, filing 0000899243-23-004819 | |
| 2023-01-09 |
Scholar Rock Holding Corp SRRK |
S, Open-market sale | 1,094 disposed | 9.48 | 10,373.31 | Form 4, filing 0000899243-23-001634 | |
| 2023-01-05 |
Scholar Rock Holding Corp SRRK |
P, Open-market purchase | 48,774 acquired | 9.33 | 455,090.68 | Form 4, filing 0000899243-23-001307 | |
| 2022-10-25 |
Scholar Rock Holding Corp SRRK |
P, Open-market purchase | 130,265 acquired | 8.04 | 1,047,382.71 | Form 4, filing 0000899243-22-034318 | |
| 2022-10-04 |
Scholar Rock Holding Corp SRRK |
P, Open-market purchase | 66,000 acquired | 7.89 | 520,759.80 | Form 4, filing 0000899243-22-033263 | |
| 2022-10-03 |
Scholar Rock Holding Corp SRRK |
P, Open-market purchase | 33,971 acquired | 7.03 | 238,788.95 | Form 4, filing 0000899243-22-033263 | |
| 2022-08-05 |
Lexicon Pharmaceuticals, Inc. LXRX |
P, Open-market purchase | 2,426,070 acquired | 2.50 | 6,065,175.00 | Form 4, filing 0000899243-22-028108 | |
| 2022-08-01 |
Lexicon Pharmaceuticals, Inc. LXRX |
P, Open-market purchase | 16,173,800 acquired | 2.50 | 40,434,500.00 | Form 4, filing 0000899243-22-027156 | |
| 2021-08-03 |
Omega Therapeutics, Inc. OMGA |
P, Open-market purchase | 875,000 acquired | 17.00 | 14,875,000.00 | Form 4, filing 0000899243-21-031304 | |
| 2021-07-30 |
Omega Therapeutics, Inc. OMGA |
P, Open-market purchase | 75,000 acquired | 16.14 | 1,210,342.50 | Form 4, filing 0000899243-21-031304 | |
| 2021-02-01 |
Seer, Inc. SEER |
S, Open-market sale | 252,545 disposed | 64.15 | 16,201,519.38 | Form 4, filing 0000899243-21-004899 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Wittouck Amaury, insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001841311
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6